{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:11:30Z","timestamp":1791483090805,"version":"4.3.4"},"reference-count":70,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014471","name":"Mundipharma Research Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014471","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Concomitant use of multiple drugs in most patients with cancer may result in drug-drug interactions (DDIs), potentially causing serious adverse effects. These patients often experience unrelieved cancer-related pain (CRP) during and after cancer treatment, which can lead to a reduced quality of life. Opioids can be used as part of a multimodal pain management strategy when non-opioid analgesics are not providing adequate pain relief, not tolerated, or are contraindicated. However, due to their narrow therapeutic window, opioids are more susceptible to adverse events when a DDI occurs. Clinically relevant DDIs with opioids are usually pharmacokinetic, mainly occurring via metabolism by cytochrome P450 (CYP). This article aims to provide an overview of potential DDIs with opioids often used in the treatment of moderate-to-severe CRP and commonly used anticancer drugs such as chemotherapeutics, tyrosine kinase inhibitors (TKIs), or biologics. A DDI-checker tool was used to contextualize the tool-informed DDI assessment outcomes with clinical implications and practice. The findings were compared to observations from a literature search conducted in Embase and PubMed to identify clinical evidence for these potential DDIs. The limited results mainly included case studies and retrospective reviews. Some potential DDIs on the DDI-checker were aligned with literature findings, while others were contradictory. In conclusion, while DDI-checkers are useful tools in identifying potential DDIs, it is necessary to incorporate literature verification and comprehensive clinical assessment of the patient before implementing tool-informed decisions in clinical practice.<\/jats:p>","DOI":"10.1093\/oncolo\/oyae094","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T12:05:56Z","timestamp":1716465956000},"page":"931-942","source":"Crossref","is-referenced-by-count":15,"title":["Opioid metabolism and drug-drug interaction in cancer"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3570-8319","authenticated-orcid":false,"given":"Matti","family":"Aapro","sequence":"first","affiliation":[{"name":"Genolier Cancer Centre, Clinique de Genolier , 1272 Genolier ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7845-2598","authenticated-orcid":false,"given":"Stefano","family":"Fogli","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Pisa , 56126 Pisa PI ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6156-880X","authenticated-orcid":false,"given":"Bart","family":"Morlion","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences, Section Anesthesiology and Algology, University of Leuven , 3000 Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4414-8934","authenticated-orcid":false,"given":"Romano","family":"Danesi","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hemato-Oncology, University of Milano , 20122 Milano MI ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"issue":"2","key":"2024110817125591000_CIT0001","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4103\/2279-042X.179560","article-title":"Drug interactions in cancer patients: a hidden risk","volume":"5","author":"Riechelmann","year":"2016","journal-title":"J Res Pharm Pract"},{"issue":"5","key":"2024110817125591000_CIT0002","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/bjc.2013.48","article-title":"Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs","volume":"108","author":"van Leeuwen","year":"2013","journal-title":"Br J Cancer"},{"issue":"11","key":"2024110817125591000_CIT0003","doi-asserted-by":"crossref","first-page":"504","DOI":"10.5414\/CPP38504","article-title":"Drug-drug interactions in medical patients: Effects of in-hospital treatment and relation to multiple drug use","volume":"38","author":"K\u00f6hler","year":"2000","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2024110817125591000_CIT0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-015-0322-7","article-title":"The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995-2010","volume":"13","author":"Guthrie","year":"2015","journal-title":"BMC Med"},{"issue":"5","key":"2024110817125591000_CIT0005","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/pds.3592","article-title":"Hospital admissions\/visits associated with drug\u2013drug interactions: a systematic review and meta-analysis","volume":"23","author":"Dechanont","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"2024110817125591000_CIT0006","first-page":"282","article-title":"Potential drug-drug interactions among hospitalized patients in a developing country","volume":"8","author":"Mousavi","year":"2017","journal-title":"Caspian J Intern Med"},{"issue":"6","key":"2024110817125591000_CIT0007","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jpainsymman.2014.03.008","article-title":"Polypharmacy in patients with advanced cancer and pain: a European cross-sectional study of 2282 patients","volume":"48","author":"Kotlinska-Lemieszek","year":"2014","journal-title":"J Pain Symptom Manage"},{"issue":"3","key":"2024110817125591000_CIT0008","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jpainsymman.2009.12.023","article-title":"The association of depression and pain with health-related quality of life, disability, and health care use in cancer patients","volume":"40","author":"Kroenke","year":"2010","journal-title":"J Pain Symptom Manage"},{"issue":"19","key":"2024110817125591000_CIT0009","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.3390\/jcm10194469","article-title":"Coping strategies, pain, and quality of life in patients with breast cancer","volume":"10","author":"O\u015bmia\u0142owska","year":"2021","journal-title":"J Clin Med"},{"issue":"7-8","key":"2024110817125591000_CIT0010","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1080\/028418698429973","article-title":"Cancer pain-a provoker of emotional, social and existential distress","volume":"37","author":"Strang","year":"1998","journal-title":"Acta Oncol"},{"key":"2024110817125591000_CIT0011","author":"IASP"},{"issue":"8","key":"2024110817125591000_CIT0012","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1007\/s00520-019-04828-8","article-title":"Opioids in cancer-related pain: current situation and outlook","volume":"27","author":"George","year":"2019","journal-title":"Support Care Cancer"},{"issue":"Suppl 4","key":"2024110817125591000_CIT0013","doi-asserted-by":"crossref","first-page":"iv166","DOI":"10.1093\/annonc\/mdy152","article-title":"Management of cancer pain in adult patients: ESMO clinical practice guidelines","volume":"29","author":"Fallon","year":"2018","journal-title":"Ann Oncol"},{"key":"2024110817125591000_CIT0014","volume-title":"WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents","author":"WHO: WHO guidelines approved by the guidelines review committee","year":"2018"},{"issue":"Suppl 11","key":"2024110817125591000_CIT0015","first-page":"S276","article-title":"Opioid pharmacokinetic drug-drug interactions","volume":"17","author":"Overholser","year":"2011","journal-title":"Am J Manag Care"},{"issue":"1","key":"2024110817125591000_CIT0016","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4321\/S1886-36552010000100006","article-title":"Drugs with narrow therapeutic index as indicators in the risk management of hospitalised patients","volume":"8","author":"Blix","year":"2010","journal-title":"Pharm Pract (Granada)"},{"key":"2024110817125591000_CIT0017","author":"FDA"},{"key":"2024110817125591000_CIT0018","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.2147\/DDDT.S86983","article-title":"Clinically significant drug-drug interactions involving opioid analgesics used for pain treatment in patients with cancer: a systematic review","volume":"9","author":"Kotlinska-Lemieszek","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"2024110817125591000_CIT0019","doi-asserted-by":"crossref","first-page":"416310","DOI":"10.3389\/fphar.2018.01145","article-title":"Drug interactions with new synthetic opioids","volume":"9","author":"P\u00e9rez-Ma\u00f1\u00e1","year":"2018","journal-title":"Front Pharmacol"},{"issue":"7","key":"2024110817125591000_CIT0020","first-page":"601","article-title":"Pharmacokinetic drug-drug interaction and their implication in clinical management","volume":"18","author":"Palleria","year":"2013","journal-title":"J Res Med Sci"},{"key":"2024110817125591000_CIT0021","author":"Liverpool_Drug_Interactions_Group"},{"issue":"1","key":"2024110817125591000_CIT0022","first-page":"451","article-title":"Global cancer statistics 2022: The trends projection analysis","volume":"10","author":"Chhikara","year":"2023","journal-title":"Chem Biol Lett"},{"issue":"3","key":"2024110817125591000_CIT0023","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2024110817125591000_CIT0024","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40122-019-00143-6","article-title":"A narrative pharmacological review of buprenorphine: a unique opioid for the treatment of chronic pain","volume":"9","author":"Gudin","year":"2020","journal-title":"Pain Therapy"},{"issue":"5","key":"2024110817125591000_CIT0025","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/bja\/ael051","article-title":"Buprenorphine induces ceiling in respiratory depression but not in analgesia","volume":"96","author":"Dahan","year":"2006","journal-title":"Br J Anaesth"},{"issue":"6","key":"2024110817125591000_CIT0026","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1097\/ALN.0b013e318238fea0","article-title":"Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active","volume":"115","author":"Brown","year":"2011","journal-title":"Anesthesiology"},{"issue":"1","key":"2024110817125591000_CIT0027","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1124\/jpet.112.193433","article-title":"P-glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociception","volume":"343","author":"Brown","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"2024110817125591000_CIT0028","doi-asserted-by":"crossref","first-page":"1758835919833867","DOI":"10.1177\/1758835919833867","article-title":"Palbociclib and ribociclib in breast cancer: Consensus workshop on the management of concomitant medication","volume":"11","author":"Bellet","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"2024110817125591000_CIT0029","author":"SmPC","year":"2022"},{"issue":"2 Suppl","key":"2024110817125591000_CIT0030","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.36076\/ppj.2008\/11\/S133","article-title":"Opioid pharmacology","volume":"11","author":"Trescot","year":"2008","journal-title":"Pain Physician"},{"key":"2024110817125591000_CIT0031","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3389\/fnagi.2016.00144","article-title":"Pharmacotherapy of pain in the older population: the place of opioids","volume":"8","author":"Prostran","year":"2016","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"2024110817125591000_CIT0032","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.eururo.2018.09.011","article-title":"The combination of enzalutamide and opioids: a painful pitfall","volume":"75","author":"Benoist","year":"2019","journal-title":"Eur Urol"},{"issue":"4","key":"2024110817125591000_CIT0033","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/j.jpainsymman.2017.11.016","article-title":"Difficulties in pain management using oxycodone and fentanyl in enzalutamide-treated patients with advanced prostate cancer","volume":"55","author":"Westdorp","year":"2018","journal-title":"J Pain Symptom Manage"},{"issue":"2","key":"2024110817125591000_CIT0034","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00132576-200406000-00006","article-title":"Suspected pharmacological interactions in a cancer patient during methadone maintenance","volume":"3","author":"Ferretti","year":"2004","journal-title":"Addictive Disorders Their Treatment"},{"key":"2024110817125591000_CIT0035","doi-asserted-by":"crossref","first-page":"S1282","DOI":"10.1016\/j.annonc.2022.07.1922","article-title":"1619P Assessment of the pharmacokinetic interaction of enzalutamide with oxycodone in men with prostate cancer: the enzyme study","volume":"33","author":"Weme","year":"2022","journal-title":"Ann Oncol"},{"issue":"suppl 7","key":"2024110817125591000_CIT0036","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1200\/jco.2015.33.7_suppl.261","article-title":"Characterizing the risk of drug-drug interactions in patients receiving enzalutamide for castration-resistant prostate cancer","volume":"33","author":"Lee","year":"2015","journal-title":"J Clin Oncol."},{"issue":"suppl 7","key":"2024110817125591000_CIT0037","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1200\/jco.2015.33.7_suppl.269","article-title":"Drug-drug interactions in patients with castration-resistant prostate cancer undergoing abiraterone therapy: characterizing the scale of the problem","volume":"33","author":"Jamani","year":"2015","journal-title":"J Clin Oncol"},{"key":"2024110817125591000_CIT0038","first-page":"A61","article-title":"4cps-099 clinically relevant drug\u2013drug interaction events in patients with abiraterone, enzalutamide or apalutamide treatment: British Medical Journal Publishing Group","author":"Bodega-Azuara","year":"2022"},{"issue":"2","key":"2024110817125591000_CIT0039","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1124\/dmd.118.084905","article-title":"Mechanisms and clinical significance of pharmacokinetic-based drug-drug interactions with drugs approved by the U.S. Food and drug administration in 2017","volume":"47","author":"Yu","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"2024110817125591000_CIT0040","doi-asserted-by":"crossref","first-page":"409001","DOI":"10.3389\/fphar.2018.01122","article-title":"Preclinical and clinical pharmacology of hydrocodone for chronic pain: a mini review","volume":"9","author":"Cardia","year":"2018","journal-title":"Front Pharmacol"},{"issue":"3","key":"2024110817125591000_CIT0041","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1046\/j.1365-2125.2003.02002.x","article-title":"CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes","volume":"57","author":"Hutchinson","year":"2004","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2024110817125591000_CIT0042","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1124\/jpet.113.207548","article-title":"In vivo activity of norhydrocodone: an active metabolite of hydrocodone","volume":"347","author":"Navani","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"2024110817125591000_CIT0043","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/cpdd.326","article-title":"Current concepts in methadone metabolism and transport","volume":"6","author":"Kharasch","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"4","key":"2024110817125591000_CIT0044","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/cpdd.137","article-title":"Drug interactions with methadone: time to revise the product label","volume":"3","author":"Greenblatt","year":"2014","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"suppl 7","key":"2024110817125591000_CIT0045","doi-asserted-by":"crossref","first-page":"S1274","DOI":"10.1016\/j.annonc.2022.07.1688","article-title":"1595p QTc-prolonging drug-drug interactions related to CDK4\/6 inhibitors","volume":"33","author":"Giraud","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"2024110817125591000_CIT0046","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2174\/157488610789869256","article-title":"Other drugs acting on nervous system associated with qt-interval prolongation","volume":"5","author":"Keller","year":"2010","journal-title":"Curr Drug Saf"},{"issue":"6","key":"2024110817125591000_CIT0047","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1592\/phco.23.6.802.32186","article-title":"Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes","volume":"23","author":"Krantz","year":"2003","journal-title":"Pharmacotherapy"},{"issue":"3","key":"2024110817125591000_CIT0048","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.clpt.2004.05.003","article-title":"Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone","volume":"76","author":"Kharasch","year":"2004","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"2024110817125591000_CIT0049","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11606-009-1225-0","article-title":"Methadone deaths: risk factors in pain and addicted populations","volume":"25","author":"Modesto-Lowe","year":"2010","journal-title":"J Gen Intern Med"},{"issue":"1","key":"2024110817125591000_CIT0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/2049463712438493","article-title":"Basic opioid pharmacology: an update","volume":"6","author":"Pathan","year":"2012","journal-title":"Br J Pain"},{"issue":"7","key":"2024110817125591000_CIT0051","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0025-6196(11)60750-7","article-title":"Opioid metabolism","volume":"84","author":"Smith","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"2024110817125591000_CIT0052","first-page":"50","article-title":"Drug interactions in cancer patients requiring concomitant chemotherapy and analgesics","volume":"13","author":"Sasu-Tenkoramaa","year":"2013","journal-title":"Pract Pain Manag"},{"issue":"8","key":"2024110817125591000_CIT0053","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1182\/blood-2010-07-294330","article-title":"Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib","volume":"117","author":"Haouala","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2024110817125591000_CIT0054","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s40262-015-0283-1","article-title":"Pharmacokinetic drug interaction studies with enzalutamide","volume":"54","author":"Gibbons","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"2024110817125591000_CIT0055","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/cpdd.934","article-title":"Evaluation of drug-drug interaction liability for buprenorphine extended-release monthly injection administered by subcutaneous route","volume":"10","author":"Kharidia","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"Suppl 1","key":"2024110817125591000_CIT0056","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.4103\/IJPC.IJPC_180_17","article-title":"Practical pharmacology of methadone: a long-acting opioid","volume":"24","author":"Sunilkumar","year":"2018","journal-title":"Indian J Palliat Care"},{"issue":"4","key":"2024110817125591000_CIT0057","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1191\/1078155203jp115oa","article-title":"Gefitinib (zd1839, iressa\u00ae): a selective epidermal growth factor receptor-tyrosine kinase inhibitor","volume":"9","author":"Shah","year":"2003","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"2024110817125591000_CIT0058","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1365-2125.2003.02053.x","article-title":"The effect of quinidine, used as a probe for the involvement of p-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone","volume":"57","author":"Kharasch","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"2024110817125591000_CIT0059","author":"SmPC","year":"2022"},{"key":"2024110817125591000_CIT0060","author":"SmPC","year":"2022"},{"issue":"6","key":"2024110817125591000_CIT0061","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2165\/00002018-200831060-00007","article-title":"Prescribers\u2019 knowledge of and sources of information for potential drug-drug interactions: a postal survey of us prescribers","volume":"31","author":"Ko","year":"2008","journal-title":"Drug Saf"},{"issue":"12","key":"2024110817125591000_CIT0062","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/00005650-200212000-00004","article-title":"Improving recognition of drug interactions: Benefits and barriers to using automated drug alerts","volume":"40","author":"Glassman","year":"2002","journal-title":"Med Care"},{"issue":"5","key":"2024110817125591000_CIT0063","first-page":"383","article-title":"Evaluation of the performance of drug-drug interaction screening software in community and hospital pharmacies","volume":"12","author":"Abarca","year":"2006","journal-title":"J Manag Care Pharm"},{"issue":"9","key":"2024110817125591000_CIT0064","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1517\/17425255.2016.1171317","article-title":"Clinical decision support systems: great promises for better management of patients\u2019 drug therapy","volume":"12","author":"Turgeon","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"2024110817125591000_CIT0065","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1586\/17512433.2014.910111","article-title":"Understanding and preventing drug\u2013drug and drug\u2013gene interactions","volume":"7","author":"Tannenbaum","year":"2014","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"5","key":"2024110817125591000_CIT0066","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jpainsymman.2019.02.006","article-title":"Clinically significant drug-drug interactions involving medications used for symptom control in patients with advanced malignant disease: a systematic review","volume":"57","author":"Kotlinska-Lemieszek","year":"2019","journal-title":"J Pain Symptom Manage"},{"issue":"2","key":"2024110817125591000_CIT0067","first-page":"64","article-title":"Screening tools used by clinical pharmacists to identify elderly patients at risk of drug-related problems on hospital admission: a systematic review","volume":"8","author":"Brady","year":"2020","journal-title":"Pharmacy (Basel, Switzerland)"},{"issue":"2","key":"2024110817125591000_CIT0068","first-page":"87","article-title":"Association of a novel medication risk score with adverse drug events and other pertinent outcomes among participants of the programs of all-inclusive care for the elderly","volume":"8","author":"Bankes","year":"2020","journal-title":"Pharmacy (Basel, Switzerland)"},{"issue":"2","key":"2024110817125591000_CIT0069","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.5210\/ojphi.v9i2.8034","article-title":"Safe opioid prescription: A SMART on FHIR approach to clinical decision support","volume":"9","author":"Sinha","year":"2017","journal-title":"Online J Public Health Inform"},{"issue":"1","key":"2024110817125591000_CIT0070","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/cts.12692","article-title":"Standardizing CYP 2D6 genotype to phenotype translation: consensus recommendations from the clinical pharmacogenetics implementation consortium and Dutch Pharmacogenetics Working Group","volume":"13","author":"Caudle","year":"2020","journal-title":"Clin Transl Sci"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/11\/931\/60541985\/oyae094.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/11\/931\/60541985\/oyae094.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T17:13:24Z","timestamp":1731086004000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/11\/931\/7680295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":70,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,5,23]]},"published-print":{"date-parts":[[2024,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae094","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,5,23]]}}}